Listed

Celldex Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2015

Filed with the SEC on Feb 23, 2016 and accepted by EDGAR at Feb 23, 2016, 10:13 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-10-01 to 2015-12-31$1.8mus-gaap:Revenues
Revenue12 months2015-01-01 to 2015-12-31$5.5mus-gaap:Revenues
Research and development12 months2015-01-01 to 2015-12-31$100.2mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2015-01-01 to 2015-12-31−$129.5mus-gaap:OperatingIncomeLoss
Net income3 months2015-10-01 to 2015-12-31−$32.7mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income12 months2015-01-01 to 2015-12-31−$127.2mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2015-10-01 to 2015-12-31−$0.33us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS12 months2015-01-01 to 2015-12-31−$1.31us-gaap:EarningsPerShareBasicAndDiluted
Capital expenditure12 months2015-01-01 to 2015-12-31$4.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-12-31$72.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-12-31$294.9mus-gaap:AssetsCurrent
Total assetsAt period end2015-12-31$337.6mus-gaap:Assets
Current liabilitiesAt period end2015-12-31$30.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-12-31$47.5mus-gaap:Liabilities
Shareholders' equityAt period end2015-12-31$290.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001047469-16-010308. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.